Researchers have found that prasinezumab, an experimental antibody treatment, may slow Parkinson's disease progression by roughly two years compared to what doctors would expect without treatment. This finding comes from five years of follow-up data in the PASADENA trial, offering hope to the over 10 million people worldwide living with this progressive neurological disorder. What Is Prasinezumab and How Does It Work? Prasinezumab is an investigational monoclonal antibody, which is a type of protein designed to target specific harmful substances in the brain. In this case, it binds to aggregated alpha-synuclein, a protein that accumulates abnormally in Parkinson's disease and damages nerve cells. By reducing the buildup of this toxic protein, prasinezumab may prevent further accumulation and stop the protein from spreading between cells, potentially slowing the disease's progression. Parkinson's disease develops when neurons that produce dopamine, a chemical messenger essential for movement control, gradually die. Currently, available treatments effectively manage motor symptoms like tremor and rigidity, but none have been shown to slow or stop the disease's underlying progression. How Much Disease Progression Can Prasinezumab Actually Prevent? The PASADENA trial's five-year data provides the most compelling evidence to date. Researchers compared participants who received prasinezumab with a virtual comparison group based on data from the Parkinson's Progression Markers Initiative (PPMI), a large observational study tracking untreated disease progression. The results were striking: on average, participants treated with prasinezumab were approximately two years less advanced in disease severity after five years compared to what the model predicted they would be without treatment. This "time saved" concept offers an intuitive way to understand the drug's potential benefit. Rather than stopping disease entirely, prasinezumab appears to slow it significantly, giving patients additional years before symptoms worsen substantially. What Does the Biological Evidence Show? Beyond clinical symptom measurements, researchers examined brain imaging biomarkers to confirm that prasinezumab is actually working at the biological level. In the PADOVA Phase IIb study, exploratory biomarker analysis revealed important changes in brain structure: - Neuromelanin Signal: Prasinezumab slowed the progressive loss of neuromelanin signal in the substantia nigra pars compacta, a brain region critical to Parkinson's pathology. - Iron Accumulation: The treatment reduced iron accumulation in the putamen, another brain area affected by Parkinson's disease. - Digital Health Tracking: Post-hoc analyses using digital health technology showed consistent trends favoring prasinezumab in measurements taken when participants were in an OFF L-DOPA state, meaning when their standard dopamine-replacement medication was not active. These imaging findings suggest that prasinezumab is biologically active and producing measurable changes in the brain structures most affected by Parkinson's disease. How to Monitor Prasinezumab's Effects in Clinical Practice As prasinezumab moves forward in development, clinicians and patients should understand how its benefits are being measured and monitored: - Motor Progression Tracking: Multiple clinical measures assess how motor symptoms like tremor, rigidity, and movement speed change over time, with prasinezumab showing sustained effects across these measures. - Brain Imaging Biomarkers: MRI scans sensitive to neuromelanin and iron can reveal whether the drug is protecting dopamine-producing neurons, providing objective biological confirmation of treatment effects. - Digital Health Technology: Wearable devices and smartphone-based assessments can detect subtle changes in movement patterns and motor function, offering real-time monitoring between clinic visits. - Long-Term Follow-Up: Extended observation periods of five years or more are necessary to confirm that treatment effects persist and that the drug continues to slow disease progression over time. What Happens Next in Prasinezumab Development? The positive five-year data from PASADENA and longer-term results from the PADOVA study have informed the initiation of the Phase III PARAISO study, which will test prasinezumab in a larger, more rigorous trial format. Phase III trials are the final stage before potential regulatory approval and involve hundreds of participants across multiple sites. "Longer term data from the PADOVA open-label extension study in early-stage Parkinson's disease showed a sustained effect of prasinezumab in slowing Parkinson's progression on top of effective symptomatic therapies," explained Tania Nikolcheva, M.D., Ph.D. at Roche. Tania Nikolcheva, M.D., Ph.D., Roche The research presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen represents a significant milestone. For decades, Parkinson's treatment has focused on managing symptoms rather than addressing the underlying disease process. A drug that can slow progression, even by two years, could meaningfully extend patients' quality of life and independence. Parkinson's disease is one of the fastest-growing neurological disorders globally, with prevalence increasing each year. The development of disease-modifying therapies like prasinezumab addresses a critical unmet need for patients and families seeking treatments that go beyond symptom relief to actually slow the disease's relentless progression.
